Matthew Gline bought $50k of ROIV
CEO at Roivant Sciences Ltd.. 3,315 shares at an average of $15.07, traded Sep 18, 2025, filed Sep 18, 2025.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- -5Relative to holdingsUnder 1% of holdings (0.0%)
- 0Price contextNear the top of the 52-week range
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +14.4%, 3m +44.4%, 6m +84.2%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001140361-25-035435, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 18, 2025 | POpen-market purchase Common Shares | +3,315 | $15.07 | $50k | 17,287,081 | Sep 18, 2025 |
Related signals
Other insiders at Roivant Sciences Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 28Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $641k 17,750 shares | -54% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.3M 200,000 shares | -11% | |
| 25Weak | Roivant Sciences Ltd. | Epperly Melissa B director | $196k 4,938 shares | -33% | |
| 20Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $203k 5,112 shares | -12% | |
| 27Weak | Roivant Sciences Ltd. | Meghan Fitzgerald director | $798k 20,000 shares | -32% | |
| 28Weak | Roivant Sciences Ltd. | Eric Venker President & Immunovant CEO | $7.2M 200,000 shares | -11% | |
| 48Moderate | Roivant Sciences Ltd. | Daniel Allen Gold director | $49M 1,438,163 shares | -10% | |
| 53Moderate | Roivant Sciences Ltd. | Keith S Manchester director | $56M 1,638,163 shares | -11% | |
| 58Moderate | Roivant Sciences Ltd. | Matthew Gline CEO | $8.4M 289,774 shares | -2% | |
| 51Moderate | Roivant Sciences Ltd. | Jennifer Humes Chief Accounting Officer | $384k 13,538 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.